These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32678721)

  • 1. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
    Buse DC; Yugrakh MS; Lee LK; Bell J; Cohen JM; Lipton RB
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine.
    Lipton RB; Lee L; Saikali NP; Bell J; Cohen JM
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1344-1352. PubMed ID: 32678720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
    Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
    J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
    [No Abstract]   [Full Text] [Related]  

  • 5. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 7. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Burden of Illness in Adult Patients with Nocturia.
    Dmochowski R; Brucker BM; Cole E; Kawahara S; Pulicharam R; Burk C; Tung A; Hale D
    J Manag Care Spec Pharm; 2019 May; 25(5):593-604. PubMed ID: 30675816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom.
    Vo P; Fang J; Bilitou A; Laflamme AK; Gupta S
    J Headache Pain; 2018 Sep; 19(1):82. PubMed ID: 30203163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
    Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
    Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.
    Gibbs SN; Shah S; Deshpande CG; Bensink ME; Broder MS; Dumas PK; Buse DC; Vo P; Schwedt TJ
    Headache; 2020 Jul; 60(7):1351-1364. PubMed ID: 32369201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine: stimulating antidepressant treatment?
    Malhi GS; Byrow Y; Cassidy F; Cipriani A; Demyttenaere K; Frye MA; Gitlin M; Kennedy SH; Ketter TA; Lam RW; McShane R; Mitchell AJ; Ostacher MJ; Rizvi SJ; Thase ME; Tohen M
    BJPsych Open; 2016 May; 2(3):e5-e9. PubMed ID: 27703782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
    Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
    Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
    Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Reported Lupus Flare Symptoms Are Associated with Worsened Patient Outcomes and Increased Economic Burden.
    Katz P; Nelson WW; Daly RP; Topf L; Connolly-Strong E; Reed ML
    J Manag Care Spec Pharm; 2020 Mar; 26(3):275-283. PubMed ID: 32105178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey.
    Kikui S; Chen Y; Todaka H; Asao K; Adachi K; Takeshima T
    J Headache Pain; 2020 Sep; 21(1):110. PubMed ID: 32912187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
    Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
    J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.